Skip To Main Content
JUERGEN METZGER on Muck Rack

JUERGEN METZGER

(He/Him)
  • Founder & Principal | Strategic Advisory – Fill & Finish | Aseptic Manufacturing, Freelance
Europe, Latin America (LatAm), Minnesota
As seen in: Pharmaceutical Technology, Pharmaceutical Online, Cell & Gene, Biosimilar Development
Covers:  Fill & Finish Aseptic Manufacturing Isolator Technology Contamination Control Strategy (CCS) Annex 1 Compliance Sterile Manufacturing Barrier Systems (Isolators & RABS) VHP / H₂O₂ Bio-Decon
Doesn't Cover: Clinical Development Drug Discovery & Research Medical Affairs Pharmacology & Toxicology Regulatory Submissions (eCTD, NDA, BLA) Quality Control Laboratory Operations Drug Formulation Developm.

Get in touch with JUERGEN

Contact JUERGEN, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

JUERGEN METZGER’s Biography

Read Full Bio →

Organization: Pharma-Technology-Consulting, LLC

Biography
Juergen is Founder & Principal of Pharma-Technology-Consulting, LLC, specializing in aseptic fill-finish, containment systems, and Annex 1 compliance. He brings nearly 30 years of experience in the pharmaceutical manufacturing industry, with a focus on isolator technology, aseptic processing, and contamination control strategies.
He began his career with Bosch Packaging Technology in 1999 and has held technical and leadership roles acros…

JUERGEN METZGER’s Journalist Portfolio

Why FAT Should Confirm Alignment, Not Reveal Its Absence

Why FAT Should Confirm Alignment, Not Reveal Its Absence

In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration…

View article →
Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality

Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality

By Juergen Metzger, Pharma-Technology-Consulting LLC In recent years, robotics, gloveless isolators, and full…

View article →
Juergen Metzger | Authors | Pharmaceutical Technology

Juergen Metzger | Authors | Pharmaceutical Technology

Juergen Metzger | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and devel…

View article →
Sterile fill finish applications for aseptic and highly potent drugs

Sterile fill finish applications for aseptic and highly potent drugs

How does a North American CDMO grow from a small legacy facility into a world-class medium-sized facility? We…

View article →

Articles

07.02.26 -- What Reliance, Annex 1, And AI Mean For The Future Of GMP

|
By Kieran Falvey, JUERGEN METZGER, Natasha Kehimkar
| Biosimilar Development Verified
Comparing Process Development Approaches For Recombinant Proteins Explore how adding a traceless tag enables streamlined affinity purification for recombinant proteins, and how this approach compares with a conventional process in development time, recovery, and purity. This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.
Open in Who Shared Issue with article?

06.30.26 -- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?

|
By JUERGEN METZGER, Aaron B. Cowley
| Cell & Gene Verified
Webinar: A Closer Look at How Single Use Consumables Drive Cost per Therapy Single-use consumables play a critical role in cell and gene therapy manufacturing, influencing cost per therapy, scalability, and operational risk. Join Invetech to explore how early consumable design decisions impact development through commercialization, where consumables add value, and how to identify cost and risk signals sooner.
Open in Who Shared Issue with article?

06.23.26 -- Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality

|
By JUERGEN METZGER
| Cell & Gene Verified
Developing a scalable, GMP-ready AAV8 production platform is complex and requires a unified approach across upstream and downstream operations, data-driven decisions, and efficient progression from bench scale to manufacturing-relevant volumes.
Open in Who Shared Issue with article?
See all 3 articles

Interview

What advice can you offer to aspiring journalists?

Be curious, ask difficult questions, and never assume that the first answer is the complete answer. In highly regulated industries such as pharmaceuticals, it is easy to focus on compliance statements, marketing claims, or headline conclusions. The most valuable insights often emerge when you dig deeper into how systems actually work, how decisions are made, and what challenges practitioners face in the real world. Technical credibility matters. Take the time to understand the science, engineering, and operational realities behind the story. The best journalism doesn't just report what happened — it helps readers understand why it happened and what can be learned from it.

What's the worst pitch you ever got?

The worst pitches are not necessarily the ones promoting a product. They are the ones that clearly haven't considered the audience. I've received messages claiming to revolutionize pharmaceutical manufacturing without addressing contamination control, process robustness, regulatory expectations, or operational reality. If a pitch relies entirely on buzzwords and marketing language while ignoring the underlying science and engineering, it quickly loses credibility. A good pitch demonstrates an understanding of the problem being solved. A great pitch demonstrates an understanding of why that problem matters.

What's the most common misperception about your beat?

The most common misconception is that compliance alone guarantees product quality and patient safety. In aseptic manufacturing, many people focus on checklists, regulations, and validation reports. While these are important, true contamination control is achieved through sound engineering, robust processes, effective risk management, and a deep understanding of how systems actually perform in operation. A compliant facility is not automatically a well-designed facility. The challenge is to bridge regulatory expectations with practical, sustainable manufacturing solutions.

Awards

2025 PDA Points to Consider No. 14: Manufacturing of A TMPs - Facility Design (Part 1 )

2025 - PDA Publication

Dear Juergen Metzger, On behalf of the PDA Board of Directors, thank you for your significant contribution to the development and publication of the 2025 PDA Points to Consider No. 14: Manufacturing of ATMPs - Facility Design (Part 1 ). This publication considers the facility, utilities, and process equipment designs necessary to support the manufacture and testing of ATMP therapies (autologous and allogeneic). lt contributes to PDA's mission to develop scientifically sound, practical technical information to advance science and regulation and thus ensure the safety of pharmaceuticals for the patients we serve. I hope you will accept the enclosed plaque and pin as a small token of our appreciation. Sincerely,

View Award